SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .
Key facts
- Who runs it
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 360 people, planned
- Started
- 11 Aug 2026
- Expected to end
- 31 Oct 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- SYH2062
- Placebo
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- ≥18 years of age, male or female at the time of signing the ICF
- Body mass index range of 18.0 ≤ BMI ≤ 37.5 kg/m2
- Untreated / Currently receiving 1-2 antihypertensive medications
- Blood pressure in the clinic during the screening period or before randomization meets 130 ≤ SBP < 170 mmHg, DBP < 110 mmHg
- Ambulatory blood pressure during the screening period meets 130 mmHg ≤ mSBP
- Participants are able to communicate well with the researchers and complete the trial according to the protocol
Who cannot take part
- Severe cardiovascular or cerebrovascular disease within 6 months prior to screening
- History of severe arrhythmia within 6 months prior to screening
- Malignant tumor within 5 years prior to screening, except for tumors expected to be curable after treatment (such as completely excised basal cell carcinoma or squamous cell carcinoma of the skin, etc.)
- Underwent major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period
- Allergy to any component of the study drug; or a clinically significant history of severe allergy
- Hypertension and secondary hypertension in special populations
- History of orthostatic hypotension
- When screening, ALT and AST > 2 times the upper limit of normal, or total bilirubin and direct bilirubin > 1.5 times the upper limit of normal
- Estimated eGFR at screening < 30 mL/min/1.73 m2
- Serum potassium level at screening > 5 mmol/L
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Mild to moderate primary hypertension
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This phase II clinical trial, involving multiple subcutaneous injections, aimed to evaluate the efficacy, safety, pharmacokinetic (PK), PD, and immunogenicity characteristics of SYH2062 injection in patients with mild to moderate essential hypertension.
The 2 groups in the trial
- SYH 2062 InjectionTreatment being tested
Treatment: SYH2062
- PlaceboPlacebo, for comparison
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension.
- Criteria questions
- Built from NCT07940075, who can take part
- Record updated
- 16 November 2026